Clinical Trials
47 trialsSANGUINE
JaxBio Ltd
Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies
NovalGen Ltd.
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma
Gilead Sciences
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma
Gilead Sciences
MALYZOMA-II
University Hospital, Strasbourg, France
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
Huazhong University of Science and Technology
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
Chinese PLA General Hospital
ProT4
University College, London
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
The University of Hong Kong
MatchCART
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
CART19
Chinese PLA General Hospital
Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
Chinese PLA General Hospital
Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer
National Cancer Institute (NCI)
Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
National Cancer Institute (NCI)
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
National Cancer Institute (NCI)
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia
National Cancer Institute (NCI)
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
National Cancer Institute (NCI)
Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Beta Alethine in Treating Patients With Low-Grade Lymphoma
National Cancer Institute (NCI)
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
National Cancer Institute (NCI)
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
National Cancer Institute (NCI)
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
National Cancer Institute (NCI)
Monoclonal Antibody Therapy in Treating Patients With Recurrent Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Who Have Not Responded to Anthracycline-Containing Combination Chemotherapy
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia
National Cancer Institute (NCI)
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
National Cancer Institute (NCI)
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
National Cancer Institute (NCI)
Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)